Download PDF
Der Klinikarzt 2013; 42(8): 350-354
DOI: 10.1055/s-0033-1356896
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Chronische lymphatische Leukämie – Standardtherapien und vielversprechende neue Behandlungsansätze

Chronic lymphocytic leukemia – Current therapeutic options and promising novel approaches
Stephan Stilgenbauer
1   Klinik für Innere Medizin III, Universitätsklinikum Ulm
› Author Affiliations
Further Information

Publication History

Publication Date:
02 September 2013 (online)

Also available at
    Permissions and Reprints

Die chronische lymphatische Leukämie (CLL) ist die häufigste Leukämie des Erwachsenen in der westlichen Welt und zeigt einen sehr variablen klinischen Verlauf. Die Heterogenität ist bedingt durch biologische Faktoren wie z. B. genomische Aberrationen und den Mutationsstatus der Immunglobulingene (IGHV). Die Therapieoptionen bei der chronisch lymphatischen Leukämie wurden über die vergangenen Jahre erheblich erweitert. Die Kombination aus Fludarabin, Cyclophosphamid und Rituximab (FCR) wurde als wirksamste Standardtherapie bei Patienten ohne relevante Komorbidität etabliert. Bendamustin kombiniert mit Rituximab (BR) wird gegenwärtig im Vergleich zu Rituximab untersucht und stellt eine Alternative dar. Chlorambucil ist weiterhin relevant bei älteren Patienten mit Komorbidität, wobei die Hinzunahme von Antikörpern eine Verbesserung bringt. Alemtuzumab ist eine Alternative für Hochrisikopatienten (refraktäre CLL, 17p Deletion, TP53 Mutation). Die allogene Stammzelltransplantation (allo-SCT) bietet die einzige kurative Option, allerdings bei relevanten Risiken. Innovative Therapieansätze fokussieren auf eine gezielte sowie individualisierte Behandlung und zeigen nach ersten Daten erhebliche Wirksamkeit bei hervorragender Verträglichkeit. Diese Übersichtsarbeit beschreibt die derzeitigen Standardtherapien und vielversprechende neue Behandlungsansätze.

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the western world and is characterized by a highly variable clinical course. Among the biological features underlying this heterogeneity, genetic lesions and the mutational status of the immunoglobulin heavy chain variable genes (IGHV) are of importance. Therapeutic options in CLL have been considerably expanded during recent years. The combination of fludarabine, cyclophosphamide and rituximab (FCR) has become gold standard in the first-line treatment of physically fit patients. Bendamustine plus Rituximab (BR) is currently evaluated in comparison to FCR and constitutes an alternative to FCR. Chlorambucil is still of relevance for elderly patients with comorbidities and the addition of antibodies appears to enhance efficacy. Alemtuzumab is an alternative for high-risk patients (refractory CLL, 17p deletion, TP53 mutation). Allogeneic stem cell transplantation (allo-SCT) offers the only chance of cure but not without substantial mortality. Innovative approaches focus on individualized, targeted therapies. A number of novel agents are in clinical trials and show marked efficacy combined with good tolerability. This review provides an overview of the current therapeutic options and of promising novel approaches.

Key words

Chronic lymphocytic leukemia (CLL) - biology - therapy
 

  • Literatur

  • 1 Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456
    CrossrefPubMedGoogle Scholar
  • 2 Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10: 37-50
    PubMedGoogle Scholar
  • 3 Catovsky D, Richards S, Matutes E et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370: 230-239
    CrossrefPubMedGoogle Scholar
  • 4 Eichhorst BF, Busch R, Hopfinger G et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885-891
    PubMedGoogle Scholar
  • 5 Keating MJ, O'Brien S, Albitar M et al. Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia. Journal of Clinical Oncology 2005; 23: 4079-4088
    CrossrefPubMedGoogle Scholar
  • 6 Hallek M, Fischer K, Fingerle-Rowson G et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-1174
    CrossrefPubMedGoogle Scholar
  • 7 Stilgenbauer S, Busch R, Schnaiter A et al. Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial. Blood ASH Annual Meeting Abstract 2012; 210
    PubMedGoogle Scholar
  • 8 Eichhorst BF, Busch R, Stilgenbauer S et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009; 114: 3382-3391
    CrossrefPubMedGoogle Scholar
  • 9 Knauf WU, Lissichkov T, Aldaoud A et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27: 4378-4384
    CrossrefPubMedGoogle Scholar
  • 10 Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554-3561
    CrossrefPubMedGoogle Scholar
  • 11 Stilgenbauer S, Zenz T, Winkler D et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009; 27: 3994-4001
    CrossrefPubMedGoogle Scholar
  • 12 Stilgenbauer S, Cymbalista F, Leblond V et al. Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gcllsg and fcgcll/MW. Blood ASH Annual Meeting Abstract 2012; 210
    PubMedGoogle Scholar
  • 13 Dreger P, Döhner H, Ritgen M et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010; 116: 2438-2447
    CrossrefPubMedGoogle Scholar
  • 14 Wierda WG, Kipps TJ, Mayer J et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 1749-1755
    CrossrefPubMedGoogle Scholar
  • 15 Chanan-Khan A, Miller KC, Musial L et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006; 24: 5343-5349
    CrossrefPubMedGoogle Scholar
  • 16 Ferrajoli A, Lee BN, Schlette EJ et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008; 111: 5291-5297
    CrossrefPubMedGoogle Scholar
  • 17 Wendtner CM, Hillmen P, Mahadevan D et al. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma 2012; 53: 417-423
    CrossrefPubMedGoogle Scholar
  • 18 Roberts AW, Seymour JF, Brown JR et al. Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease. Journal of Clinical Oncology 2012; 30: 488-496
    CrossrefPubMedGoogle Scholar
  • 19 Wiestner A. Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies. J Clin Oncol 2013; 31: 128-130
    CrossrefPubMedGoogle Scholar
  • 20 Hoellenriegel J, Meadows SA, Sivina M et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011; 118: 3603-3612
    CrossrefPubMedGoogle Scholar
  • 21 Coutre SE, Leonard J, Furman R et al. Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study. Blood ASH Annual Meeting Abstract 2012; 210
    PubMedGoogle Scholar
  • 22 Advani RH, Buggy JJ, Sharman JP et al. Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies. J Clin Oncol 2013; 31: 88-94
    CrossrefPubMedGoogle Scholar
  • 23 Byrd JC, Furman RF, Coutre SE et al. The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study. Blood ASH Annual Meeting Abstract 2012; 210
    PubMedGoogle Scholar